We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Your Password has changed! Please login again
Cart
Outdated Browser Detected
Our website has detected that you are using an outdated browser that will prevent you from accessing certain features.
Please use one of the below recommended browsers to improve your browsing experience
In the latest installment of our video series, West on the Road, we travel across the Atlantic to our manufacturing facility in Eschweiler, Germany. There we meet Manager of Process Engineering Martin Rothstein, who says he’s impressed at how often he has encountered West products in his private life, whether visiting a family member in the hospital or during a vaccination appointment for one of his two small children.
Rothstein and the teams at the Eschweiler facility produce high-value pharmaceutical packaging products, turning materials into high-quality elastomeric stoppers, plungers and other components for the biotech and pharmaceutical industries. With the biopharmaceutical industry experiencing a shift toward patient-centered, quality care, it is increasingly important to maintain strict manufacturing processes to decrease risk. With this in mind, Rothstein explains that for many customers, it’s important to work with a provider such as West that manufacturers all of the various packaging components for a drug product under one roof, ensuring minimal risk.
The teams at Eschweiler have a long history of providing high-quality components; they possess a deep knowledge of the production process and are able to provide the right support to the customers to help them improve patient care around the world. Check out this new video to learn more about the work being done at West’s Eschweiler facility and visit our Careers page to learn more bout working at West in Germany.
On Saturday, July 13, a team of West colleagues and family members participated in the 2013 Merrell Down & Dirty National Mud and Obstacle Series in Philadelphia, Pa. The run is a 10k with a series of obstacles including: <a href="http://www.downanddirtymudrun.com/obstacles/straw-bales-slippery-mountain/"><span style="color: #0000ff; text-decoration: underline;">slippery mountain and inflatable</span></a>, <a href="http://www.downanddirtymudrun.com/obstacles/mud-pit-water-crossings/"><span style="color: #0000ff; text-decoration: underline;">mud pit and water crossings</span></a>, and <a href="http://www.downanddirtymudrun.com/obstacles/marine-hurdles-cargo-net-climb/"><span style="color: #0000ff; text-decoration: underline;">Marine hurdles and cargo net climb</span></a>.
West associates at the Williamsport and Jersey Shore, Pa. facilities recently honored veterans at the First Annual Veteran’s Day parade. Decked out in West fleece jackets and carrying a West banner, a group of 45 associates and family members marched through Williamsport to honor members of the armed forces who are presently serving or who have served the country. The group distributed candy and West key chains to onlookers as they made their way to city hall, where Jim Collins, Jersey Shore Director of Operations, served as a parade judge.
A key element of West’s commitment to a safe and efficient delivery of drug products is staying abreast of industry developments, and being prepared to help customers navigate them. Recently Dow Corning introduced a new product - Dow Corning® 366 35% Dimethicone NF Emulsion.
On September 7th, 2023, a long-awaited final guidance was issued by the Food and Drug Administration (FDA) - Application of Human Factors Engineering Principles for Combination Products: Questions and Answers. The document is intended to be used in conjunction with other human factors related guidance and available national and international standards, such as AAMI HE75 and IEC 62366. In this latest guidance, the agency provides its view on best practices for conducting human factors activities for combination products either comprised of a device and a drug or a device and biologic.
The level of particles in parenteral pharmaceutical formulations is a critical quality attribute. This is no surprise; the clinical consequence of their presence can be very severe, including fatality. In the major pharmacopeia, from the US, Europe, and Japan, there is a specified limit for particles in the final parenteral formulation. Moreover, these pharmacopeia specify two methods for measurement – light obscuration (LO) and microscopic particle count (MPC).